16.01.2017
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN publishes annual report and confirms preliminary financials for fiscal year 2015/16
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Miscellaneous/Final Results
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN
publishes annual report and confirms preliminary financials for fiscal year
2015/16
16.01.2017 / 15:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
BRAIN publishes annual report and confirms preliminary financials for
fiscal year 2015/16
Zwingenberg, January 16, 2017: Just less than one year after the IPO,
B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG";
ISIN DE0005203947 / WKN 520394) today publishes its first annual report as
a listed company, confirming the preliminary figures for the fiscal year
2015/16. These had been announced on December 19, 2016, already.
Accordingly, during the reporting period from October 1, 2015 to September
30, 2016, the BRAIN-Group slightly increased its total operating
performance to EUR 26.1 million from EUR 25.7 million in the previous year.
In Q4 2015/16 alone, the total operating performance of the Group increased
by 18% compared to Q3 2015/16. The yearly revenues of both Group segments
"BioIndustrial" and "BioScience" increased by 8% to EUR 22.8 million.
The fiscal year 2015/16 was significantly influenced by the IPO in February
2016 with its related costs and one-off effects as well as by partly
difficult market developments. Nonetheless, the company continues to expect
the EBIT break-even to be achieved as planned in fiscal year 2017/18.
The Management Board is still satisfied with the past financial year: "The
successful course of our IPO shows that the bioeconomy is accepted and
understood as a future-oriented topic and is also indisputably recognized
in capital market circles as a future sector. It is our aim to establish
BRAIN long-term and sustainably as a substantial market participant of the
bio-based economy", says Jürgen Eck, CEO of BRAIN AG.
For many years, BRAIN has been reporting on the company's work in quarterly
reports which have won multiple communications and design awards. In
addition to the audited group financials and discussions, the BRAIN annual
report, entitled "Engineering Biology", also provides exciting insights
into the world of biodiversity, BRAIN's own BioArchive, the product
pipeline, more detailed information on the strategic partnerships and
selected programs of the BRAIN-Group, as well as a summary of the
highlights of the financial year.
The annual report can now be accessed at www.brain-biotech.de/investor-
relations/financial-publications/. Upon request, a printed copy can be sent
by post as soon as it is available.
About BRAIN
BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at www.brain-
biotech.de/en
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: [email protected]
www.brain-biotech.de
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any forward-
looking statements.
---------------------------------------------------------------------------
16.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
536589 16.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN